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ABSTRACT 
Primary hyperparathyroidism is a common endocrine disorder, characterized by an inappropriate 
increase in serum parathyroid hormone (PTH) levels. It is most often caused by a single benign 
parathyroid tumor. The elevated PTH levels cause an increase in serum calcium 
levels, which in turn may present diffuse neuromuscular symptoms, as well as increased risk of 
cardiovascular complications. Malignant parathyroid tumors are rare. They have a poor prognosis and 
constitute a diagnostic challenge for the pathologist. 
Studies on hereditary syndromes with parathyroid tumor manifestations have identified a number of 
genes involved in parathyroid tumorigenesis. The etiology of the common sporadic parathyroid 
adenoma, however, is yet to be explained. Since postmenopausal women constitute the most frequently 
affected group of patients, the involvement of female endocrine hormones has been suggested. The aim 
of this thesis was to elucidate the molecular pathophysiology of this disease, mapping molecular 
aberrations and endocrine signaling within these tumors. 
By a limited screening of the Wingless signaling cascade we identified a number of aberrantly 
expressed proteins. Changes included the proteins glycogen synthase kinase 3 β, and 
Adenomatosis Polyposis Coli. Loss of the latter was distinguishingly restricted to malignant 
parathyroid tumors, thus being a candidate diagnostic marker of parathyroid malignancy. 
(Paper I) 
The S37A mutation in the CTNNB1 gene, encoding β-catenin was suggested to be a significant 
event in the development of sporadic parathyroid tumors. We evaluated this hypothesis by 
mutational analysis of 98 parathyroid tumors. Finding no S37A CTNNB1 mutations, we suggest 
that this genetic variant has a limited significance in development of primary 
hyperparathyroidism. (Paper II) 
Several indications suggested the involvement of prolactin signaling in parathyroid physiology 
and tumor development. By tumor protein and ribonucleic acid analysis we could identify an 
overall high receptor expression as compared to other tissues. We showed that physiological 
levels of prolactin were able to affect PTH secretion and alter gene expression in parathyroid 
tumor cells. As compared to normal parathyroid tissue, the levels and distribution of the receptor was 
altered in parathyroid adenomas. In all, the findings support a possible link between prolactin signaling 
and parathyroid tumors. (Paper III) 
We also evaluated the expression of estrogen receptor isoforms in parathyroid tumors. Previous 
data suggested that the parathyroid glands are targets of estrogen signaling, but that they lacked 
estrogen receptor (ER) expression. We re-evaluated the ER expression, including recently 
identified isoforms. Our results suggest that parathyroid tissue lack ERα, but express ER β1 and 
βcx isoforms. Parathyroid tumors showed decreased ER β1 expression, with an inverse 
correlation to increasing tumor weight. Treatment of primary parathyroid cultures with an ER β1-
specific ligand showed changes in transcriptional activity significantly analogous with nuclear ER 
transcriptional activity and apoptosis of tumor cells. Thus, this gene expression profiling suggests tumor 
suppressive properties of ER β1 in the parathyroid glands. (Paper IV) 
Much work remains in elucidating the molecular changes that characterize parathyroid 
tumors. Our data suggests that female hormone receptors, either during the course of life or 
the menopausal changes, may play a role in the development and presentation of primary 
hyperparathyroidism.	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